AXLRx AstraZeneca intelligence — Pulmonology in United States: 1 report covering Pulmonology in United States.
Tagrisso dominant in first-line EGFR+ NSCLC; Alexion complement franchise (Ultomiris/Soliris) holds strong specialty access.
The COPD maintenance fight has moved past the inhaler. Two 2024 approvals, ensifentrine and dupilumab, opened the first genuinely novel mechanisms in a decade and split the market into an inhaler base and a biology-defined add-on tier.
We use analytics cookies to see how visitors use AXLRx. They're only set if you accept — decline and none are placed. See our Privacy Policy.